Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07052903 · ClinicalTrials.gov registry record · Phase 3
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
A Phase 3 study of Transthyretin Amyloidosis With Cardiomyopathy, sponsored by Alnylam Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,250
- Enrollment target
- 20
- Study locations
NCT07052903: Recruiting Phase 3 study of Transthyretin Amyloidosis With Cardiomyopathy, sponsored by Alnylam Pharmaceuticals.
NCT07052903 is a Phase 3 study of Transthyretin Amyloidosis With Cardiomyopathy that is actively recruiting participants, run by Alnylam Pharmaceuticals. The registered enrollment target is 1,250 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07052903, a Phase 3 study of Transthyretin Amyloidosis With Cardiomyopathy, is actively recruiting participants, sponsored by Alnylam Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,250 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to: * Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events * Evaluate the efficacy of nucresiran compared to placebo on additional assessments of CV events and/or death * Evaluate the efficacy of nucresiran compared to placebo on patient-reported health status and health-related quality of life
Primary Outcome
All-cause mortality and recurrent CV events (CV hospitalizations and urgent HF visits) will be compared between treatment groups using an Andersen-Gill model.
Conditions Studied
Interventions
- DRUG Nucresiran
- DRUG Sterile Normal Saline (0.9% NaCl)
Study Locations (20)
Georgia
- Clinical Trial Site - Atlanta
- Clinical Trial Site - Gainesville
- Clinical Trial Site - Tucker
New York
- Clinical Trial Site - Manhasset
- Clinical Trial Site - New York
- Clinical Trial Site - The Bronx
Indiana
- Clinical Trial Site - Indianapolis
- Clinical Trial Site - Indianapolis
Pennsylvania
- Clinical Trial Site - Lancaster
- Clinical Trial Site - Philadelphia
California
- Clinical Trial Site - La Jolla
District of Columbia
- Clinical Trial Site - Washington D.C.
Florida
- Clinical Trial Site - Brandon
Kansas
- Clinical Trial Site - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,250 participants |
| Start Date | 2025-07-02 |
| Est. Completion | 2032-11-30 |
| Phase | Phase 3 |
What NCT07052903 shows while recruiting
NCT07052903 is an interventional study that assigns participants to a tested intervention. Its 1,250 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% higher).
The record links to 1 condition, with Transthyretin Amyloidosis With Cardiomyopathy appearing as the primary indexed condition, and to 2 interventions - of which Nucresiran is the first listed.
NCT07052903 names 20 study sites across 14 states, led by Georgia, New York, Indiana.
Frequently Asked Questions
What is clinical trial NCT07052903 about?
NCT07052903 is a clinical study titled "TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy". The purpose of this study is to: * Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events * Evaluate the efficacy of nucresiran compared to placebo on additional assessments of CV events and/or death * Evaluate the efficacy of nucresir...
What is the current status of trial NCT07052903?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,250 participants. The study started on 2025-07-02. Estimated completion is 2032-11-30.
What conditions does trial NCT07052903 study?
This clinical trial studies the following conditions: Transthyretin Amyloidosis With Cardiomyopathy.
What interventions are being tested in trial NCT07052903?
The interventions under investigation include: Nucresiran (DRUG), Sterile Normal Saline (0.9% NaCl) (DRUG).
Who is sponsoring clinical trial NCT07052903?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07052903 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transthyretin Amyloidosis With Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07052903's enrollment target sits among peer trials
1,250 207th of 2000 higher than 1,792 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02743858 · 1,250 participants
Lymphedema Surveillance Study
- NCT04670874 · 1,250 participants
Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
- NCT04807868 · 1,250 participants
AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
- NCT05995821 · 1,250 participants
Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI